4.4 Article

Coronavirus disease-2019 in cancer patients. A report of the first 25 cancer patients in a western country (Italy)

期刊

FUTURE ONCOLOGY
卷 16, 期 20, 页码 1425-1432

出版社

FUTURE MEDICINE LTD
DOI: 10.2217/fon-2020-0369

关键词

cancer patients and COVID-19; cobicistat; darunavir; hydroxychloroquine; infection and cancer; lopinavir; oncology and coronavirus; ritonavir

类别

向作者/读者索取更多资源

Background: We describe cancer patients with coronavirus disease-2019 (COVID-19) infection treated at the Piacenza's general hospital (north Italy). Materials & methods: 25 cancer patients infected by COVID-19 admitted at the Piacenza's general hospital from 21 February to 18 March 2020. Outcome from the infection were compared with infected noncancer patients. Results: 20 patients (80%) were treated with antiviral therapy and hydroxychloroquine and five (20%) received hydroxychloroquine alone. Nine (36%) patients died, while 16 (64%) overcome the infection. In the control group the mortality was 16.13% and the overcome from infection was 83.87%. Conclusion: Mortality for COVID-19 was greater in cancer patients when compared with noncancer patients, worse prognosis for older age, women and patients treated with hydroxychloroquine alone. However, the comparisons did not reach statistical significance in most cases. This could be due to the small sample size that is the main limitation of the study.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据